AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,376.00p
   
  • Change Today:
    -224.00p
  • 52 Week High: 12,696.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.26m
  • Volume: 1,715,496
  • Market Cap: £191,860m
  • RiskGrade: 123

AstraZeneca's Imfinzi gets FDA approval for lung cancer treatment

By Frank Prenesti

Date: Friday 11 Nov 2022

LONDON (ShareCast) - (Sharecast News) - AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
The approval by the Food and Drug Administration (FDA) was based on the results from the Poseidon Phase 3 trial.

Patients treated with a limited course of five cycles of Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,376.00p
Change Today -224.00p
% Change -1.78 %
52 Week High 12,696.00
52 Week Low 9,501.00
Volume 1,715,496
Shares Issued 1,550.26m
Market Cap £191,860m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.62% below the market average92.62% below the market average92.62% below the market average92.62% below the market average92.62% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
70.38% above the market average70.38% above the market average70.38% above the market average70.38% above the market average70.38% above the market average
88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average
Income
92.94% below the market average92.94% below the market average92.94% below the market average92.94% below the market average92.94% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.70% above the market average82.70% above the market average82.70% above the market average82.70% above the market average82.70% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 9
Buy 16
Neutral 5
Sell 0
Strong Sell 1
Total 31
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 11-Jun-2024

Time Volume / Share Price
17:26 1,169 @ 12,377.96p
17:26 47 @ 12,377.64p
17:26 579 @ 12,377.91p
17:26 66,685 @ 12,377.97p
17:26 15,155 @ 12,377.97p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page